Zinc chelating agents for depleting XIAP and sensitizing tumor cells to apoptosis
The invention provides zinc chelating agents and formulations thereof that deplete XIAP in cancer cells and sensitize the cells to apoptosis-inducing agents. The invention provides methods for sensitizing apoptosis-resistant cancer cells to apoptosis-inducing agents, as well as methods for treating a subject with a combined therapy of a zinc chelating agent and an apoptosis-inducing agent.
1. A method for inducing apoptosis in an apoptosis-resistant cell, comprising contacting an apoptosis-resistant cell with a compound selected from the group consisting of Formula I,
Formula II,
Formula V,
wherein X1 is H, CI, or F and X2 is CN or F, and a pharmaceutically acceptable salt thereof, in an amount of effective to deplete X-linked inhibitor of apoptosis protein (XIAP) in the cell, and contacting the cell with an amount of an apoptosis-inducing agent effective to induce apoptosis in the cell.
2. The method of claim 1 , wherein the compound is Formula I,
or a pharmaceutically acceptable salt thereof.
3. The method of claim 1 , wherein the compound is Formula II,
or a pharmaceutically acceptable salt thereof.
4. The method of claim 1 , wherein the compound is Formula V,
wherein X1 is H, CI, or F and X2 is CN or F, or a pharmaceutically acceptable salt thereof.
5. The method of claim 1 , wherein the apoptosis-inducing agent is TNF-related apoptosis-inducing ligand (TRAIL).
6. The method of claim 1 , wherein the cell is a tumor cell.
7. The method of claim 6 , wherein the tumor cell is a prostate tumor cell.
8. The method of claim 7 , wherein the prostate tumor cell is a castration resistant prostate tumor cell.
9. The method of claim 1 , wherein the compound substantially depletes XIAP in the cell.
10. A method for treating a tumor, comprising administering to a subject in need thereof a compound selected from the group consisting of Formula I,
Formula II,
Formula V,
wherein X1 is H, CI, or F and X2 is CN or F, and a pharmaceutically acceptable salt thereof, in an amount of effective to deplete X-linked inhibitor of apoptosis protein (XIAP) XIAP in cells of the tumor, and administering to the subject an apoptosis-inducing agent in an amount of effective to induce apoptosis in cells of the tumor in which XIAP has been depleted, thereby treating the tumor.
11. The method of claim 10 , wherein the compound is Formula I,
or a pharmaceutically acceptable salt thereof.
12. The method of claim 10 , wherein the compound is Formula II,
or a pharmaceutically acceptable salt thereof.
13. The method of claim 10 , wherein the compound is Formula V,
wherein X1 is H, Cl, or F and X2 is CN or F, or a pharmaceutically acceptable salt thereof.
14. The method of claim 10 , wherein the apoptosis-inducing agent is TNF-related apoptosis-inducing ligand (TRAIL).
15. The method of claim 10 , wherein the tumor is an apoptosis-resistant tumor.
16. The method of claim 10 , wherein the tumor is a tumor of the prostate gland.
17. The method of claim 16 , wherein the tumor of the prostate gland is a castration resistant tumor of the prostate gland.
18. The method of claim 10 , wherein the compound substantially depletes XIAP in cells of the tumor.